ArticlePharmacoEconomics - open2019
International HTA Experience with Targeted Therapy Approvals for Lung Cancer.
Article in PharmacoEconomics - open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan.PharmacoEconomics - open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to compare the listing success rates and time incurred to listing of recently approved lung cancer medications across Australia, Canada and England.
methodsA comparison between the three countries was performed with respect to the listing status, time incurred for listing and differences in recommendations made for cost effectiveness. Major uncertainties and limitations that compromise health technology assessment (HTA) recommendations were identified.
resultsThe listing success rate was found to be low across all three countries (33% Canada, 17% England and 8% Australia). Across the HTA agencies' reviews, comparators were either dissimilar or altered for effectiveness and/or economic analysis. Overall, limited evidence was found for all indications, and uncertainties were identified due to indirect analyses (70%) and survival extrapolation (100%). Although most of the indications were concluded to be not cost effective, some were subsequently listed (47%) at a reduced price and/or with a specific access programme.
conclusionsThis study demonstrated a low listing success rate for novel lung therapies internationally within different HTA jurisdictions. Major uncertainties that are resistant to available solutions seem to be common across different countries; thus, international solutions would be beneficial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.